Cargando…
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases
[Image: see text] Multidrug resistant Gram-negative bacterial infections are an increasing public health threat due to rapidly rising resistance toward β-lactam antibiotics. The hydrolytic enzymes called β-lactamases are responsible for a large proportion of the resistance phenotype. β-Lactamase inh...
Autores principales: | Durand-Réville, Thomas F., Comita-Prevoir, Janelle, Zhang, Jing, Wu, Xiaoyun, May-Dracka, Tricia L., Romero, Jan Antoinette C., Wu, Frank, Chen, April, Shapiro, Adam B., Carter, Nicole M., McLeod, Sarah M., Giacobbe, Robert A., Verheijen, Jeroen C., Lahiri, Sushmita D., Sacco, Michael D., Chen, Yu, O’Donnell, John P., Miller, Alita A., Mueller, John P., Tommasi, Rubén A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927146/ https://www.ncbi.nlm.nih.gov/pubmed/32658473 http://dx.doi.org/10.1021/acs.jmedchem.0c00579 |
Ejemplares similares
-
Pharmacokinetic/Pharmacodynamic
Determination and Preclinical Pharmacokinetics of the β-Lactamase
Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282
por: O’Donnell, John, et al.
Publicado: (2020) -
Interactions of the Diazabicyclooctane Serine β-Lactamase
Inhibitor ETX1317 with Target Enzymes
por: Shapiro, Adam B., et al.
Publicado: (2020) -
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
por: Shapiro, Adam B., et al.
Publicado: (2021) -
694. In vitro Antibacterial Activity of Sulbactam–Durlobactam (ETX2514SUL) Against 121 Recent Acinetobacter baumannii Isolated from Patients in India
por: Miller, Alita, et al.
Publicado: (2019) -
709. In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam–Durlobactam (ETX2514SUL) Against Pathogenic Burkholderia Species
por: O’Donnell, John, et al.
Publicado: (2019)